_edited.png)
.jpg)
About Therapain5
Therapain5 is dedicated to disrupting the status quo in chronic pain management. Founded by Dr. Gilbert Blaise, we are committed to developing innovative treatments that enhance patient outcomes and reduce healthcare costs. Our mission is to bring to market products that can empower physicians to deliver effective treatments to patients suffering from moderate-to-severe chronic pain, significantly improving their quality of care and life.
"Our goal is to transform chronic pain management, making effective and safe treatments accessible to those who need them most."
- Dr. Gilbert Blaise -
A Revolutionary Approach
GBM-5 combines five complementary drugs in precise ratios, targeting multiple pain pathways for effective relief with minimal side effects. This innovative treatment offers new hope for patients with refractory chronic pain and Complex Regional Pain Syndrome (CRPS).
_edited_edited.png)
Key Benefits
GBM-5’s unique formulation acts on pain and inflammation modulation, providing a safer and more effective alternative to traditional pain medications. The low-dosage combination minimizes side effects and reduces the risk of dependency.
Administration Routes
GBM-5 is designed for flexibility and convenience, available in three administration routes: intrathecal for severe, refractory chronic pain; nasal spray for easy administration suitable for chronic pain; and topical cream for superficial pain and as a complement to other treatments.
Proven Effectiveness
In initial trials, patients experienced significant pain relief, with pain levels dropping from 9-10 to 1-2 on the Numeric Rating Scale. These promising results have led to Health Canada’s approval for phase IIa clinical trials.
Clinical Trials and Research
Therapain5’s GBM-5 has shown promising results in early clinical trials. Due to its success in initial human trials, we have received approval from Health Canada to proceed directly to phase IIa clinical trials. These trials aim to further evaluate the efficacy and safety of GBM-5 in treating pain associated with Complex Regional Pain Syndrome (CRPS) and refractory chronic pain (RCP)
.jpg)
Patient Success Stories
This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now.
- Name Here -
This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now.
- Name Here -
This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now. This will be a success story. This is filler text for now.
- Name Here -
.jpg)
For Investors
Therapain5 is seeking financial support to complete clinical trials and bring GBM-5 to market. The chronic pain market is vast, with over 65 million people in North America and Europe suffering from refractory chronic pain. Our goal is to raise $15M USD to fund phase IIa clinical trials and expedite the approval process. Investing in Therapain5 offers an opportunity to be part of a transformative solution in chronic pain management, with significant market potential and a strong IP portfolio.